| Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response. | |
| | |
MedLine Citation:
|
PMID: 18384519 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: It remains unclear how we can shorten the treatment duration of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C virus (HCV) genotype 2 infection who achieved a rapid virological response (RVR). AIM: We compared the efficacy of antiviral combination therapy with peginterferon and ribavirin for 8 vs. 24 weeks for the treatment of patients with HCV genotype 2 infection and with RVR. METHODS: Sixty-one patients were enrolled. Serum HCV RNA was not detected at 4 weeks after the start of treatment in 32 patients with an RVR. These 32 patients were randomly assigned to 8-week (n=15) or 24-week (n=17) treatment regimens. Patients in the 8-week group who relapsed underwent a 24-week retreatment. RESULTS: No significant difference in patient characteristics was observed between the 8- and the 24-week treatment groups. A sustained virological response (SVR) was seen in five of 15 patients (33.3%) in the 8-week treatment group and 14 of 17 (82.4%) in the 24-week treatment group; the rate was significantly higher in the 24-week treatment group (P=0.0140). Nine of 10 relapsed patients in the 8-week treatment group underwent a 24-week retreatment, and seven achieved an SVR. CONCLUSION: An 8-week regimen of combination antiviral therapy with peginterferon and ribavirin yielded an increase in the relapse rate, indicating the limitation of a reduction of treatment below 12 weeks in patients with genotype 2, after RVR. |
| | |
Authors:
|
Hidenori Toyoda; Takashi Kumada; Seiki Kiriyama; Yasuhiro Sone; Makoto Tanikawa; Yasuhiro Hisanaga; Akira Kanamori; Hiroyuki Atsumi; Satoshi Nakano; Takahiro Arakawa |
Related Documents
:
|
17151339 - Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset ... 11262659 - Efficacy of interferon alfa-2a in severe and refractory uveitis associated with behçet... 9836109 - Efficacy of high dose of recombinant alpha 2b interferon on long term response in chron... 2110199 - Lack of suppression of ige production by recombinant interferon gamma: a controlled tri... 2792319 - Bone marrow morphology during alpha-interferon treatment in hairy cell leukemia. 10721659 - Complete remission of hypereosinophilic syndrome after interferon-alpha therapy: report... 22744589 - Late results of surgical treated scoliosis with the use of selective and extend instrum... 9448879 - Inappropriate sinus tachycardia (ist): management by radiofrequency modification of sin... 20582879 - biliary stent occlusion |
Publication Detail:
|
Type: Comparative Study; Journal Article; Randomized Controlled Trial Date: 2008-04-01 |
Journal Detail:
|
Title: Liver international : official journal of the International Association for the Study of the Liver Volume: 29 ISSN: 1478-3231 ISO Abbreviation: Liver Int. Publication Date: 2009 Jan |
Date Detail:
|
Created Date: 2009-01-05 Completed Date: 2009-03-09 Revised Date: 2009-04-26 |
Medline Journal Info:
|
Nlm Unique ID: 101160857 Medline TA: Liver Int Country: England |
Other Details:
|
Languages: eng Pagination: 120-5 Citation Subset: IM |
Affiliation:
|
Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan. tkumada@he.mirai.ne.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antiviral Agents / administration & dosage, pharmacology, therapeutic use* Drug Therapy, Combination Female Hepacivirus / drug effects, genetics* Hepatitis C, Chronic / drug therapy*, genetics Humans Interferon Alfa-2a / administration & dosage, pharmacology, therapeutic use* Male Middle Aged Polyethylene Glycols / administration & dosage, pharmacology, therapeutic use* Ribavirin / administration & dosage, pharmacology, therapeutic use* Statistics, Nonparametric Viremia |
| Chemical | |
Reg. No./Substance:
|
0/Antiviral Agents; 0/Polyethylene Glycols; 0/peginterferon alfa-2a; 36791-04-5/Ribavirin; 76543-88-9/Interferon Alfa-2a |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The Aspergillus nidulans FcyB cytosine-purine scavenger is highly expressed during germination and i...
Next Document: Is serum alanine transaminase level a reliable marker of histological disease in chronic hepatitis C...